Novo Nordisk Raises 2026 Revenue Forecast on Weight-Loss Pill Growth

Novo Nordisk raised its 2026 revenue forecast after strong weight-loss drug sales.

The company expects sales to range between a 2% drop and 2% growth.

Its previous forecast predicted a sales decline of up to 6%.

Higher demand for GLP-1 products drove the updated business outlook.

These treatments include diabetes drug Ozempic and obesity medication Wegovy.

Sales for the new Wegovy pill reached 5.4 billion Danish kroner in Q3.

The pill option provides an alternative to weekly injection pens.

The weight-loss pill is currently sold in eight international markets.

Novo Nordisk recently announced plans to launch the pill in Australia.

However, the company has not announced a launch date for Danish pharmacies.

Total third-quarter revenue reached 79.2 billion Danish kroner for the company.

Quarterly net profit reached 16.7 billion Danish kroner despite recent write-downs.

Write-downs involved production equipment and a failed heart medication project.

CPH Post reported the earnings update for the Danish pharmaceutical giant.